Mercer Global Advisors Inc. ADV Buys 12,981 Shares of PerkinElmer, Inc. (NYSE:PKI)

Mercer Global Advisors Inc. ADV raised its stake in PerkinElmer, Inc. (NYSE:PKIGet Rating) by 157.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 21,250 shares of the medical research company’s stock after purchasing an additional 12,981 shares during the period. Mercer Global Advisors Inc. ADV’s holdings in PerkinElmer were worth $4,273,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Amundi Pioneer Asset Management Inc. grew its holdings in shares of PerkinElmer by 1.3% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 128,822 shares of the medical research company’s stock valued at $12,413,000 after buying an additional 1,695 shares during the last quarter. Kestra Advisory Services LLC grew its holdings in shares of PerkinElmer by 29.2% during the third quarter. Kestra Advisory Services LLC now owns 2,106 shares of the medical research company’s stock valued at $365,000 after buying an additional 476 shares during the last quarter. Signaturefd LLC grew its holdings in shares of PerkinElmer by 11.1% during the third quarter. Signaturefd LLC now owns 1,803 shares of the medical research company’s stock valued at $312,000 after buying an additional 180 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of PerkinElmer by 6.8% during the third quarter. Commonwealth Equity Services LLC now owns 16,157 shares of the medical research company’s stock valued at $2,799,000 after buying an additional 1,023 shares during the last quarter. Finally, Banque Cantonale Vaudoise grew its holdings in shares of PerkinElmer by 221.8% during the third quarter. Banque Cantonale Vaudoise now owns 6,819 shares of the medical research company’s stock valued at $1,182,000 after buying an additional 4,700 shares during the last quarter. 81.95% of the stock is owned by hedge funds and other institutional investors.

PerkinElmer stock traded up $0.14 during midday trading on Tuesday, hitting $160.52. 13,352 shares of the stock were exchanged, compared to its average volume of 867,515. PerkinElmer, Inc. has a 52-week low of $126.75 and a 52-week high of $203.16. The stock has a market capitalization of $20.25 billion, a price-to-earnings ratio of 19.87, a price-to-earnings-growth ratio of 0.50 and a beta of 1.10. The business’s 50-day moving average price is $174.70 and its 200-day moving average price is $178.28. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.70.

PerkinElmer (NYSE:PKIGet Rating) last released its quarterly earnings results on Tuesday, February 1st. The medical research company reported $2.56 earnings per share for the quarter, topping the consensus estimate of $2.15 by $0.41. PerkinElmer had a net margin of 18.40% and a return on equity of 23.73%. The business had revenue of $1.36 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the previous year, the company earned $3.96 earnings per share. The firm’s revenue for the quarter was up .7% compared to the same quarter last year. On average, sell-side analysts predict that PerkinElmer, Inc. will post 6.92 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, May 13th. Shareholders of record on Friday, April 22nd will be paid a $0.07 dividend. This represents a $0.28 dividend on an annualized basis and a yield of 0.17%. The ex-dividend date of this dividend is Thursday, April 21st. PerkinElmer’s payout ratio is 3.47%.

Separately, StockNews.com assumed coverage on shares of PerkinElmer in a report on Thursday, March 31st. They set a “hold” rating for the company. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, PerkinElmer currently has an average rating of “Buy” and an average target price of $166.37.

In other PerkinElmer news, insider Daniel R. Tereau sold 6,696 shares of the business’s stock in a transaction dated Monday, March 14th. The shares were sold at an average price of $165.84, for a total value of $1,110,464.64. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.52% of the stock is owned by insiders.

PerkinElmer Profile (Get Rating)

PerkinElmer, Inc provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services.

See Also

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKIGet Rating).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.